{"id":"https://openalex.org/W2554368482","doi":"https://doi.org/10.1182/blood.v106.11.4076.4076","title":"A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.","display_name":"A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.","publication_year":2005,"publication_date":"2005-11-16","ids":{"openalex":"https://openalex.org/W2554368482","doi":"https://doi.org/10.1182/blood.v106.11.4076.4076","mag":"2554368482"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v106.11.4076.4076","doi":"https://doi.org/10.1182/blood.v106.11.4076.4076","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v106.11.4076.4076","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108785086","display_name":"Jerry Sherman Powell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160527","display_name":"University of California Davis Medical Center","ror":"https://ror.org/05t6gpm70","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160527","https://openalex.org/I4210160856"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jerry Sherman Powell","raw_affiliation_strings":["Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA","institution_ids":["https://openalex.org/I4210160527"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Thierry Lambert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210162942","display_name":"Bic\u00eatre Hospital","ror":"https://ror.org/05c9p1x46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210162942","https://openalex.org/I4405259118"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Thierry Lambert","raw_affiliation_strings":["Centre de Traitement des He\u0301mophiles, Ho\u0302pital de Bice\u0302tre AP-HP, Le Kremlin Bice\u0302tre, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre de Traitement des He\u0301mophiles, Ho\u0302pital de Bice\u0302tre AP-HP, Le Kremlin Bice\u0302tre, France","institution_ids":["https://openalex.org/I4210097159","https://openalex.org/I4210162942"]}]},{"author_position":"middle","author":{"id":null,"display_name":"F. Herna\u0301ndez Navarro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"F. Herna\u0301ndez Navarro","raw_affiliation_strings":["Congenital Coagulopathies, Hospital La Paz, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Congenital Coagulopathies, Hospital La Paz, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018280451","display_name":"Michael Recht","orcid":"https://orcid.org/0000-0002-2805-1016","observed_orcids":["https://orcid.org/0000-0002-2805-1016"]},"institutions":[{"id":"https://openalex.org/I4210124153","display_name":"Phoenix Children's Hospital","ror":"https://ror.org/03ae6qy41","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210124153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Recht","raw_affiliation_strings":["The Hemophilia Center, Phoenix Children\u2019s Hospital, Phoenix, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Hemophilia Center, Phoenix Children\u2019s Hospital, Phoenix, AZ, USA","institution_ids":["https://openalex.org/I4210124153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062275112","display_name":"Sharon T. Sullivan","orcid":"https://orcid.org/0000-0002-4327-666X","observed_orcids":["https://orcid.org/0000-0002-4327-666X"]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon T. Sullivan","raw_affiliation_strings":["Clinical Research and Development, Wyeth, Cambridge MA and Collegeville PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research and Development, Wyeth, Cambridge MA and Collegeville PA, USA","institution_ids":["https://openalex.org/I4403928396"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085388496","display_name":"Chandrasekhar Udata","orcid":"https://orcid.org/0009-0003-7938-5432","observed_orcids":["https://orcid.org/0009-0003-7938-5432"]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chandrasekhar Udata","raw_affiliation_strings":["Clinical Research and Development, Wyeth, Cambridge MA and Collegeville PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research and Development, Wyeth, Cambridge MA and Collegeville PA, USA","institution_ids":["https://openalex.org/I4403928396"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072062025","display_name":"Leslie C. Lilly","orcid":"https://orcid.org/0000-0002-3232-0645","observed_orcids":["https://orcid.org/0000-0002-3232-0645"]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leslie C. Lilly","raw_affiliation_strings":["Clinical Research and Development, Wyeth, Cambridge MA and Collegeville PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research and Development, Wyeth, Cambridge MA and Collegeville PA, USA","institution_ids":["https://openalex.org/I4403928396"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034488510","display_name":"David A. Roth","orcid":"https://orcid.org/0000-0001-8356-0457","observed_orcids":["https://orcid.org/0000-0001-8356-0457"]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David A. Roth","raw_affiliation_strings":["Clinical Research and Development, Wyeth, Cambridge MA and Collegeville PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research and Development, Wyeth, Cambridge MA and Collegeville PA, USA","institution_ids":["https://openalex.org/I4403928396"]}]},{"author_position":"last","author":{"id":null,"display_name":"The rFIX-R Study Group","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"The rFIX-R Study Group","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.31086324,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"106","issue":"11","first_page":"4076","last_page":"4076"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hemophilia-b","display_name":"hemophilia B","score":0.8989999890327454},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.9440000057220459},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8019999861717224},{"id":"https://openalex.org/keywords/ionic-strength","display_name":"ionic strength","score":0.9110000133514404},{"id":"https://openalex.org/keywords/sodium-chloride","display_name":"sodium chloride","score":0.6629999876022339},{"id":"https://openalex.org/keywords/red-blood-cell-agglutination","display_name":"red blood cell agglutination","score":0.8939999938011169},{"id":"https://openalex.org/keywords/prophylaxis","display_name":"prophylaxis","score":0.875},{"id":"https://openalex.org/keywords/on-demand-treatment","display_name":"on-demand treatment","score":0.7979999780654907},{"id":"https://openalex.org/keywords/factor-ix-activity","display_name":"factor IX activity","score":0.5770000219345093},{"id":"https://openalex.org/keywords/hemorrhage-control","display_name":"hemorrhage control","score":0.44999998807907104},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.5389999747276306},{"id":"https://openalex.org/keywords/thrombosis","display_name":"thrombosis","score":0.5019999742507935},{"id":"https://openalex.org/keywords/allergic-reactions","display_name":"allergic reactions","score":0.36899998784065247}],"concepts":[{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.9424986839294434},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7390230894088745},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.7029498219490051},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5967294573783875},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.583494246006012},{"id":"https://openalex.org/C2781221834","wikidata":"https://www.wikidata.org/wiki/Q425360","display_name":"Factor IX","level":2,"score":0.5717241168022156},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5537993907928467},{"id":"https://openalex.org/C43376680","wikidata":"https://www.wikidata.org/wiki/Q6580786","display_name":"Bolus (digestion)","level":2,"score":0.4792763888835907},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41098135709762573},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3647448718547821},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2987977862358093},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.29479098320007324},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27834299206733704},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v106.11.4076.4076","doi":"https://doi.org/10.1182/blood.v106.11.4076.4076","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v106.11.4076.4076","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1969941406","https://openalex.org/W2005221472","https://openalex.org/W2594513432","https://openalex.org/W2007679389","https://openalex.org/W1748744250","https://openalex.org/W2140241119","https://openalex.org/W2992995566","https://openalex.org/W2116114354","https://openalex.org/W60481422","https://openalex.org/W2981193300"],"abstract_inverted_index":{"Abstract":[0],"A":[1],"new":[2,31,55,367],"formulation":[3,32,126,368],"(rFIX-R)":[4],"of":[5,14,25,69,110,116,122,127,185,205,211,224,228,237,254,282,300,339,354,360,365,392],"BeneFIX":[6,134,222],"has":[7],"been":[8,303,322],"developed":[9],"to":[10,35,158,190,221,239,263,265,311,319,409],"reduce":[11],"the":[12,21,26,37,41,49,67,103,111,113,123,168,172,183,196,200,212,215,225,234,244,290,358,363,366,374],"possibility":[13],"RBC":[15,341],"agglutination,":[16,342],"a":[17,54,136,145,336,384],"phenomenon":[18],"associated":[19,348],"with":[20,86,120,193,289,305,335,390,395],"low":[22],"ionic":[23,38],"strength":[24,39,52,58],"reconstituted":[27],"drug":[28],"product.":[29],"The":[30,175,271,351],"contains":[33],"NaCl":[34],"increase":[36],"and":[40,53,95,230,285,362,369],"recombinant":[42],"factor":[43,162,178,206,273],"IX":[44,163,179,207,274],"concentration":[45],"is":[46,373],"increased":[47,396],"for":[48,219,251,261,379],"1000":[50,296],"IU":[51,57,299],"2000":[56],"by":[59],"reconstituting":[60],"all":[61],"strengths":[62],"in":[63,72,97,398],"5":[64],"mL,":[65],"facilitating":[66],"administration":[68],"larger":[70,400],"doses":[71,401],"decreased":[73,406],"volumes.":[74],"Thirty-four":[75],"(34)":[76],"previously":[77],"treated":[78,96],"(\u2265150":[79],"exposure":[80],"days":[81],"[EDs])":[82],"males":[83],"(\u226512":[84],"years)":[85],"moderately":[87],"severe/severe":[88],"hemophilia":[89],"B":[90],"(FIX:C":[91],"\u22642%)":[92],"were":[93,118,150],"enrolled":[94],"this":[98,355],"2":[99],"part":[100],"study.":[101],"In":[102,243],"randomized,":[104],"double-blind,":[105],"crossover":[106],"pharmacokinetic":[107],"(PK)":[108],"period":[109],"study,":[112],"PK":[114,202,293],"characteristics":[115],"rFIX-R":[117,132,186,220,250,283,292,320,361,386],"compared":[119,288],"those":[121],"currently":[124],"available":[125],"BeneFIX.":[128,194,370,410],"Subjects":[129,165],"received":[130,167],"either":[131],"or":[133,330],"as":[135],"75":[137],"IU/kg":[138],"bolus":[139],"infusion":[140,184],"over":[141,155],"10":[142],"minutes":[143],"after":[144,182,279],"suitable":[146],"washout.":[147],"Blood":[148],"samples":[149],"collected":[151],"at":[152,267],"defined":[153],"times":[154],"72":[156],"hours":[157],"measure":[159],"pre-/post-infusion":[160],"plasma":[161,177,272],"activity.":[164],"then":[166],"alternate":[169],"treatment":[170,246,284],"following":[171],"same":[173],"procedure.":[174],"mean":[176,201],"activity-versus-time":[180,275],"profile":[181,276],"was":[187,277,286],"essentially":[188],"identical":[189],"that":[191,391,399],"seen":[192],"From":[195],"26":[197],"evaluable":[198],"subjects,":[199],"parameter":[203],"estimates":[204],"activity":[208],"establish":[209],"bioequivalence":[210,235,364,372],"products":[213],"since":[214],"90%":[216],"confidence":[217],"intervals":[218],"ratios":[223],"geometric":[226],"means":[227],"Cmax":[229],"AUCs":[231],"fell":[232],"within":[233],"interval":[236],"80%":[238],"125%.":[240],"Figure":[241,242],"open-label":[245],"period,":[247],"subjects":[248],"used":[249],"on-demand":[252],"control":[253],"bleeding,":[255],"routine":[256],"prophylaxis,":[257],"and/or":[258],"surgical":[259],"prophylaxis":[260],"6-":[262],"12-months":[264],"achieve":[266],"least":[268],"30":[269],"EDs.":[270],"recharacterized":[278],"6":[280],"months":[281],"unchanged":[287],"baseline":[291],"profile.":[294],"Over":[295],"infusions":[297],"(>3,500,000":[298],"rFIX-R)":[301],"have":[302,321],"administered":[304,404],"no":[306],"serious":[307],"adverse":[308,316,349],"events":[309,317],"related":[310,318],"rFIX-R.":[312],"No":[313],"clinically":[314],"significant":[315],"reported,":[323],"including":[324],"FIX":[325],"inhibitor":[326],"development,":[327],"allergic-type":[328],"manifestations,":[329],"thrombotic":[331],"complications.":[332],"One":[333],"subject,":[334],"prior":[337],"history":[338],"frequent":[340],"reported":[343],"two":[344],"instances":[345],"without":[346],"any":[347],"events.":[350],"overall":[352],"results":[353],"study":[356],"demonstrate":[357],"safety":[359],"Since":[371],"most":[375],"important":[376],"surrogate":[377],"endpoint":[378],"efficacy,":[380],"these":[381],"data":[382],"predict":[383],"favorable":[385],"efficacy":[387],"profile,":[388],"consistent":[389],"BeneFIX,":[393],"but":[394],"convenience":[397],"can":[402],"be":[403],"using":[405],"volumes":[407],"relative":[408]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-11-30T00:00:00"}